FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155925029> ?p ?o ?g. }

• W2155925029 endingPage "1398" @default.
• W2155925029 startingPage "1391" @default.
• W2155925029 abstract "ObjectiveEndograft mural thrombus has been associated with stent graft or limb thrombosis after endovascular aneurysm repair (EVAR). This study aimed to identify clinical and morphologic determinants of endograft mural thrombus accumulation and its influence on thromboembolic events after EVAR.MethodsA prospectively maintained database of patients treated by EVAR at a tertiary institution from 2000 to 2012 was analyzed. Patients treated for degenerative infrarenal abdominal aortic aneurysms and with available imaging for thrombus analysis were considered. All measurements were performed on three-dimensional center-lumen line computed tomography angiography (CTA) reconstructions. Patients with thrombus accumulation within the endograft's main body with a thickness >2 mm and an extension >25% of the main body's circumference were included in the study group and compared with a control group that included all remaining patients. Clinical and morphologic variables were assessed for association with significant thrombus accumulation within the endograft's main body by multivariate regression analysis. Estimates for freedom from thromboembolic events were obtained by Kaplan-Meier plots.ResultsSixty-eight patients (16.4%) presented with endograft mural thrombus. Median follow-up time was 3.54 years (interquartile range, 1.99-5.47 years). In-graft mural thrombus was identified on 30-day CTA in 22 patients (32.4% of the study group), on 6-month CTA in 8 patients (11.8%), and on 1-year CTA in 17 patients (25%). Intraprosthetic thrombus progressively accumulated during the study period in 40 patients of the study group (55.8%). Overall, 17 patients (4.1%) presented with endograft or limb occlusions, 3 (4.4%) in the thrombus group and 14 (4.1%) in the control group (P = .89). Thirty-one patients (7.5%) received an aortouni-iliac (AUI) endograft. Two endograft occlusions were identified among AUI devices (6.5%; overall, 0.5%). None of these patients showed thrombotic deposits in the main body, nor were any outflow abnormalities identified on the immediately preceding CTA. Estimated freedom from thromboembolic events at 5 years was 95% in both groups (P = .97). Endograft thrombus accumulation was associated with >25% proximal aneurysm neck thrombus coverage at baseline (odds ratio [OR], 1.9; 95% confidence interval [CI], 1.1-3.3), neck length ≤15 mm (OR, 2.4; 95% CI, 1.3-4.2), proximal neck diameter ≥30 mm (OR, 2.4; 95% CI, 1.3-4.6), AUI (OR, 2.2; 95% CI, 1.8-5.5), or polyester-covered stent grafts (OR, 4.0; 95% CI, 2.2-7.3) and with main component “barrel-like” configuration (OR, 6.9; 95% CI, 1.7-28.3).ConclusionsMural thrombus formation within the main body of the endograft is related to different endograft configurations, main body geometry, and device fabric but appears to have no association with the occurrence of thromboembolic events over time. Endograft mural thrombus has been associated with stent graft or limb thrombosis after endovascular aneurysm repair (EVAR). This study aimed to identify clinical and morphologic determinants of endograft mural thrombus accumulation and its influence on thromboembolic events after EVAR. A prospectively maintained database of patients treated by EVAR at a tertiary institution from 2000 to 2012 was analyzed. Patients treated for degenerative infrarenal abdominal aortic aneurysms and with available imaging for thrombus analysis were considered. All measurements were performed on three-dimensional center-lumen line computed tomography angiography (CTA) reconstructions. Patients with thrombus accumulation within the endograft's main body with a thickness >2 mm and an extension >25% of the main body's circumference were included in the study group and compared with a control group that included all remaining patients. Clinical and morphologic variables were assessed for association with significant thrombus accumulation within the endograft's main body by multivariate regression analysis. Estimates for freedom from thromboembolic events were obtained by Kaplan-Meier plots. Sixty-eight patients (16.4%) presented with endograft mural thrombus. Median follow-up time was 3.54 years (interquartile range, 1.99-5.47 years). In-graft mural thrombus was identified on 30-day CTA in 22 patients (32.4% of the study group), on 6-month CTA in 8 patients (11.8%), and on 1-year CTA in 17 patients (25%). Intraprosthetic thrombus progressively accumulated during the study period in 40 patients of the study group (55.8%). Overall, 17 patients (4.1%) presented with endograft or limb occlusions, 3 (4.4%) in the thrombus group and 14 (4.1%) in the control group (P = .89). Thirty-one patients (7.5%) received an aortouni-iliac (AUI) endograft. Two endograft occlusions were identified among AUI devices (6.5%; overall, 0.5%). None of these patients showed thrombotic deposits in the main body, nor were any outflow abnormalities identified on the immediately preceding CTA. Estimated freedom from thromboembolic events at 5 years was 95% in both groups (P = .97). Endograft thrombus accumulation was associated with >25% proximal aneurysm neck thrombus coverage at baseline (odds ratio [OR], 1.9; 95% confidence interval [CI], 1.1-3.3), neck length ≤15 mm (OR, 2.4; 95% CI, 1.3-4.2), proximal neck diameter ≥30 mm (OR, 2.4; 95% CI, 1.3-4.6), AUI (OR, 2.2; 95% CI, 1.8-5.5), or polyester-covered stent grafts (OR, 4.0; 95% CI, 2.2-7.3) and with main component “barrel-like” configuration (OR, 6.9; 95% CI, 1.7-28.3). Mural thrombus formation within the main body of the endograft is related to different endograft configurations, main body geometry, and device fabric but appears to have no association with the occurrence of thromboembolic events over time." @default.
• W2155925029 created "2016-06-24" @default.
• W2155925029 creator A5001281663 @default.
• W2155925029 creator A5002567352 @default.
• W2155925029 creator A5004726448 @default.
• W2155925029 creator A5009101387 @default.
• W2155925029 creator A5019406968 @default.
• W2155925029 creator A5046156442 @default.
• W2155925029 creator A5060772900 @default.
• W2155925029 creator A5087993384 @default.
• W2155925029 date "2015-06-01" @default.
• W2155925029 modified "2023-10-02" @default.
• W2155925029 title "Clinical outcome and morphologic determinants of mural thrombus in abdominal aortic endografts" @default.
• W2155925029 cites W1553442175 @default.
• W2155925029 cites W1965593286 @default.
• W2155925029 cites W1970321175 @default.
• W2155925029 cites W2007255921 @default.
• W2155925029 cites W2012975064 @default.
• W2155925029 cites W2027194562 @default.
• W2155925029 cites W2040528764 @default.
• W2155925029 cites W2040993376 @default.
• W2155925029 cites W2041233324 @default.
• W2155925029 cites W2045572533 @default.
• W2155925029 cites W2045655445 @default.
• W2155925029 cites W2055717701 @default.
• W2155925029 cites W2058071190 @default.
• W2155925029 cites W2064713117 @default.
• W2155925029 cites W2064792862 @default.
• W2155925029 cites W2066019002 @default.
• W2155925029 cites W2066945340 @default.
• W2155925029 cites W2067639198 @default.
• W2155925029 cites W2071111819 @default.
• W2155925029 cites W2080685691 @default.
• W2155925029 cites W2087022049 @default.
• W2155925029 cites W2094113144 @default.
• W2155925029 cites W2099989755 @default.
• W2155925029 cites W2100850234 @default.
• W2155925029 cites W2111515035 @default.
• W2155925029 cites W2112500668 @default.
• W2155925029 cites W2115028678 @default.
• W2155925029 cites W2116625999 @default.
• W2155925029 cites W2120426322 @default.
• W2155925029 cites W2133068451 @default.
• W2155925029 cites W2133586257 @default.
• W2155925029 cites W2146132623 @default.
• W2155925029 cites W2146751527 @default.
• W2155925029 cites W2148874426 @default.
• W2155925029 cites W2156507070 @default.
• W2155925029 cites W2156798468 @default.
• W2155925029 cites W2157242620 @default.
• W2155925029 doi "https://doi.org/10.1016/j.jvs.2015.01.032" @default.
• W2155925029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25736781" @default.
• W2155925029 hasPublicationYear "2015" @default.
• W2155925029 type Work @default.
• W2155925029 sameAs 2155925029 @default.
• W2155925029 citedByCount "21" @default.
• W2155925029 countsByYear W21559250292015 @default.
• W2155925029 countsByYear W21559250292016 @default.
• W2155925029 countsByYear W21559250292017 @default.
• W2155925029 countsByYear W21559250292018 @default.
• W2155925029 countsByYear W21559250292019 @default.
• W2155925029 countsByYear W21559250292020 @default.
• W2155925029 countsByYear W21559250292021 @default.
• W2155925029 countsByYear W21559250292022 @default.
• W2155925029 countsByYear W21559250292023 @default.
• W2155925029 crossrefType "journal-article" @default.
• W2155925029 hasAuthorship W2155925029A5001281663 @default.
• W2155925029 hasAuthorship W2155925029A5002567352 @default.
• W2155925029 hasAuthorship W2155925029A5004726448 @default.
• W2155925029 hasAuthorship W2155925029A5009101387 @default.
• W2155925029 hasAuthorship W2155925029A5019406968 @default.
• W2155925029 hasAuthorship W2155925029A5046156442 @default.
• W2155925029 hasAuthorship W2155925029A5060772900 @default.
• W2155925029 hasAuthorship W2155925029A5087993384 @default.
• W2155925029 hasBestOaLocation W21559250291 @default.
• W2155925029 hasConcept C119060515 @default.
• W2155925029 hasConcept C126838900 @default.
• W2155925029 hasConcept C131631996 @default.
• W2155925029 hasConcept C141071460 @default.
• W2155925029 hasConcept C2776098176 @default.
• W2155925029 hasConcept C2776543907 @default.
• W2155925029 hasConcept C2778583881 @default.
• W2155925029 hasConcept C2779993416 @default.
• W2155925029 hasConcept C2780643987 @default.
• W2155925029 hasConcept C2780868729 @default.
• W2155925029 hasConcept C2781347138 @default.
• W2155925029 hasConcept C2781362458 @default.
• W2155925029 hasConcept C71924100 @default.
• W2155925029 hasConceptScore W2155925029C119060515 @default.
• W2155925029 hasConceptScore W2155925029C126838900 @default.
• W2155925029 hasConceptScore W2155925029C131631996 @default.
• W2155925029 hasConceptScore W2155925029C141071460 @default.
• W2155925029 hasConceptScore W2155925029C2776098176 @default.
• W2155925029 hasConceptScore W2155925029C2776543907 @default.
• W2155925029 hasConceptScore W2155925029C2778583881 @default.
• W2155925029 hasConceptScore W2155925029C2779993416 @default.
• W2155925029 hasConceptScore W2155925029C2780643987 @default.
• W2155925029 hasConceptScore W2155925029C2780868729 @default.

• next